Danaher Co. (NYSE:DHR) Shares Bought by Principal Securities Inc.

Principal Securities Inc. grew its position in shares of Danaher Co. (NYSE:DHR) by 4.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 14,979 shares of the conglomerate’s stock after acquiring an additional 668 shares during the quarter. Principal Securities Inc.’s holdings in Danaher were worth $3,438,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. AMF Tjanstepension AB bought a new stake in shares of Danaher during the third quarter valued at about $5,923,000. Creative Planning raised its stake in shares of Danaher by 3.1% during the third quarter. Creative Planning now owns 126,340 shares of the conglomerate’s stock valued at $35,125,000 after purchasing an additional 3,749 shares in the last quarter. Good Life Advisors LLC bought a new stake in shares of Danaher during the third quarter valued at about $217,000. Howard Capital Management Group LLC raised its stake in shares of Danaher by 4.1% during the third quarter. Howard Capital Management Group LLC now owns 1,229 shares of the conglomerate’s stock valued at $342,000 after purchasing an additional 48 shares in the last quarter. Finally, Cyndeo Wealth Partners LLC raised its stake in shares of Danaher by 9.7% during the third quarter. Cyndeo Wealth Partners LLC now owns 8,425 shares of the conglomerate’s stock valued at $2,342,000 after purchasing an additional 748 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Up 1.5 %

DHR opened at $206.66 on Tuesday. Danaher Co. has a fifty-two week low of $196.80 and a fifty-two week high of $281.70. The business has a 50-day moving average of $229.53 and a 200-day moving average of $249.13. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The company has a market capitalization of $149.26 billion, a PE ratio of 39.14, a price-to-earnings-growth ratio of 2.68 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter in the prior year, the firm posted $2.09 earnings per share. Equities research analysts forecast that Danaher Co. will post 7.67 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Friday, December 27th were paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.52%. The ex-dividend date of this dividend was Friday, December 27th. Danaher’s dividend payout ratio (DPR) is presently 20.45%.

Insider Activity at Danaher

In related news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 11.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have commented on DHR shares. KeyCorp boosted their price target on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. TD Cowen boosted their price target on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. Citigroup cut their price objective on Danaher from $285.00 to $265.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Robert W. Baird cut their price objective on Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a report on Tuesday, January 28th. Finally, UBS Group reduced their price target on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Seven investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.